Capricor Therapeutics, Inc.
$20.35
The Read: Capricor’s stock surged about 29% after FDA lifted its Complete Response Letter and strong Phase 3 data boosted commercial prospects, then dropped about 16% due to a costly legal dispute forcing solo commercialization.
Price
Overlays
Panel
CAPR
Hover to view data
No Data